LLY - Erasca Eli Lilly to collaborate on trial to evaluate combo treatment for two cancers
- Erasca ( NASDAQ: ERAS ) on Monday said it had entered into a clinical trial collaboration and supply agreement with Eli Lilly ( LLY ) to support its ongoing phase 1/1b FLAGSHP-1 trial.
- ERAS stock +4.8% to $6.97 in premarket trading
- The early-stage trial will evaluate ERAS' inhibitor ERAS-601 in combination with Lilly's ( LLY ) antibody cetuximab for the treatment of a type of cancer of the colon and the skin called triple wildtype metastatic colorectal cancer and human papillomavirus-negative advanced head and neck squamous cell carcinoma, respectively.
- Erasca ( ERAS ) is the trial's sponsor, while LLY will supply cetuximab at no cost.
- ERAS had previously signed collaboration and supply agreements with LLY and Pfizer ( PFE ) to evaluate a combination of cetuximab and PFE's encorafenib with its inhibitor ERAS-007.
For further details see:
Erasca, Eli Lilly to collaborate on trial to evaluate combo treatment for two cancers